Detailed information for compound 1999547
Basic information
Technical information
- Name: Unnamed compound
- MW: 372.463 | Formula: C23H24N4O
-
H donors: 2
H acceptors: 2
LogP: 4.51
Rotable bonds: 3
Rule of 5 violations (Lipinski): 1 - SMILES: COc1cc(ccc1C(C#Cc1c(C)nc(nc1N)N)C)c1ccccc1C
- InChi: 1S/C23H24N4O/c1-14-7-5-6-8-18(14)17-10-12-19(21(13-17)28-4)15(2)9-11-20-16(3)26-23(25)27-22(20)24/h5-8,10,12-13,15H,1-4H3,(H4,24,25,26,27)
- InChiKey: QLSDCZWWZVSFDC-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Cryptosporidium parvum | dihydrofolate reductase-thymidylate synthase | Starlite/ChEMBL | No references |
| Homo sapiens | dihydrofolate reductase | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | dihydrofolate reductase | 187 aa | 202 aa | 29.7 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Echinococcus multilocularis | dihydrofolate reductase | 0.026 | 0.9883 | 1 |
| Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.026 | 0.9883 | 1 |
| Brugia malayi | Dihydrofolate reductase | 0.026 | 0.9883 | 1 |
| Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0262 | 1 | 0.5 |
| Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.026 | 0.9883 | 1 |
| Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0262 | 1 | 0.5 |
| Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0262 | 1 | 0.5 |
| Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0262 | 1 | 0.5 |
| Echinococcus granulosus | dihydrofolate reductase | 0.026 | 0.9883 | 1 |
| Brugia malayi | dihydrofolate reductase family protein | 0.026 | 0.9883 | 1 |
| Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0262 | 1 | 0.5 |
| Schistosoma mansoni | dihydrofolate reductase | 0.026 | 0.9883 | 1 |
| Chlamydia trachomatis | dihydrofolate reductase | 0.026 | 0.9883 | 0.5 |
| Onchocerca volvulus | 0.013 | 0 | 0.5 | |
| Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.026 | 0.9883 | 1 |
| Loa Loa (eye worm) | dihydrofolate reductase | 0.026 | 0.9883 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 36 nM | Spectrophotometric Enzyme Assay | BINDINGDB. | No reference |
| IC50 (binding) | = 2770 nM | BindingDB_Patents: Spectrophotometric Enzyme Assay. Compounds were evaluated in spectrophotometric enzyme assays using ChDHFR-TS and hDHFR. Inhibition constants (IC50) were measured (see Table 4). The lead compound, X, has an inhibition constant of 38 nM and modest selectivity (8-fold). All of the biphenyl compounds are more potent than the initial lead compound X and exhibit greater selectivity for the pathogenic enzyme. The most potent racemic compound, D(rac), a 5'-biphenyl derivative, is also the most selective of the racemic compounds (944-fold). The single R enantiomer of this 5'-biphenyl analog is the most potent (1.1 nM) and most selective (1273-fold) of all known compounds tested against the Cryptosporidium DHFR enzyme. | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL3644517
Bibliographic References
No literature references available for this target.
If you have references for this compound, please enter them in a user comment (below) or Contact us.